How can we help?
Avoid blind spots in your market. Get the insights you need to accelerate innovation.
Los Angeles, CA November 26, 2019 – At DeciBio, we believe that the precision medicine revolution will be driven by improvements in life science research tools and diagnostics technologies! A couple of weeks ago, I had the privilege to be a panelist at the UBS EMEA 2019 conference in London, with James Hadfield and Doris-Ann Williams. I made the following points, which generated an interesting discussion following the conference (the slides can be found here for those who want to follow along): https://bit.ly/2On9BRR
Slide 2: Today, cancer has a major societal impact, with 18M new cases and 10M deaths in 2018; this will change in a decade
Slide 3: Liquid biopsies and immuno-oncology drugs (including checkpoint inhibitors and CAR-T) are the two recent developments that can move the needle for cancer patients
Slide 4: Liquid biopsy is a “companion” (not a CDx) through the entire cancer journey; it has many advantages over other procedures that are currently the standard of care, such as imaging and IHC from tissue biopsies
Slide 5: Therefore, liquid biopsies, and most notably early detection, have the opportunity to change the cancer care paradigm, and potentially shift the demographics in developed countries, as we detect cancer earlier, when survival is much higher
Slide 6: As a result, it’s an exciting space that has attracted hundreds of companies that have received billions in combined VC investments in the last 5 years
Slide 7: Liquid biopsies for cancer are just the beginning; there is a lot of information we’ll be getting from blood draws in the future
Slide 8: This transformation of the diagnostic landscape will impact multiple stakeholders, from pharma companies to payors and patients
Now, diagnostic companies “just” have to price accordingly and move away from the current cost-based / fee-for-service model.
Feel free to contact us if you’d like to chat about this topic! #NGSisUnstoppable
Author: Stephane Budel, Partner at DeciBio Consulting, LLC
Connect with Stephane Budel on Linkedin
Disclaimer: Companies listed above may be DeciBio clients and/or customers